Core Viewpoint - Alkermes reported mixed financial results for Q4 2025, with adjusted earnings beating estimates but total revenues declining year-over-year, raising questions about future performance and investor sentiment [2][3][12]. Financial Performance - Adjusted earnings from continuing operations were 46 cents per share, surpassing the Zacks Consensus Estimate of 43 cents, but down from $1.04 per share in the same quarter last year [2]. - Total revenues for Q4 2025 were $384.5 million, a decrease of 10.6% from the previous year, yet still exceeding the Zacks Consensus Estimate of $380 million [3]. Product Sales - Sales from proprietary products grew 2.5% year-over-year to $315.5 million, driven by strong demand for Lybalvi, aligning with management's guidance of $300-$320 million [5]. - Vivitrol sales decreased by 7.5% year-over-year to $124.1 million, while Aristada sales increased by 0.6% to $97.2 million, both exceeding their respective consensus estimates [5][6]. - Lybalvi generated sales of $94.1 million, up 22.2% year-over-year, with total prescriptions growing by 25% [6]. Revenue Breakdown - Manufacturing and royalty revenues fell approximately 43.4% year-over-year to $69.1 million, with specific contributions from Biogen's Vumerity and other products [6][7]. - Research and development expenses rose by 59.8% year-over-year to $93 million, primarily due to ongoing studies on alixorexton [7]. Cash Position - As of December 31, 2025, Alkermes had cash and cash equivalents of $1.32 billion, an increase from $1.14 billion on September 30, 2025 [8]. 2026 Guidance - The company anticipates total revenues between $1.73 billion and $1.84 billion for 2026, driven mainly by net sales of proprietary products expected to be in the range of $1.52 billion to $1.60 billion [9]. - Specific product sales forecasts include Vivitrol at $460-$480 million, Aristada at $365-$385 million, and Lybalvi at $380-$400 million, with newly acquired Lumryz expected to generate $315-$335 million [10]. Expense Projections - Research and development expenses are projected to be between $445 million and $485 million, while selling, general, and administrative expenses are expected to range from $890 million to $930 million [11]. Market Sentiment - There has been a downward trend in estimates revisions over the past two months, indicating a cautious outlook among investors [12]. - Alkermes currently holds a Zacks Rank 5 (Strong Sell), suggesting expectations of below-average returns in the near term [14].

Core Insights - Alkermes plc (ALKS) reported adjusted earnings of 46 cents per share for Q4 2025, surpassing the Zacks Consensus Estimate of 43 cents, but down from $1.04 per share in the same quarter last year [1] - Total revenues for Q4 were $384.5 million, a decrease of 10.6% year over year, primarily due to lower manufacturing and royalty revenues, yet still beating the Zacks Consensus Estimate of $380 million [2] - Despite the earnings beat, ALKS shares fell by 7% following the announcement, with a 7.1% increase in share price over the past six months compared to a 23% rise in the industry [2] Financial Performance - Alkermes' proprietary product sales grew by 2.5% year over year to $315.5 million in Q4, driven by strong demand for Lybalvi, aligning with management's guidance of $300-$320 million [4] - Sales of Vivitrol decreased by 7.5% year over year to $124.1 million, while Aristada sales increased by 0.6% to $97.2 million, both exceeding their respective Zacks Consensus Estimates [7] - Lybalvi generated sales of $94.1 million, up 22.2% year over year, with total prescriptions increasing by 25% [8] Revenue Breakdown - Manufacturing and royalty revenues fell approximately 43.4% year over year to $69.1 million, with specific contributions from Biogen's Vumerity at $27.6 million and royalties from Xeplion and certain Invega products at $31.3 million [9] - For the full year 2025, Alkermes reported revenues of $1.48 billion, reflecting a 5.1% decline year over year, with earnings from continuing operations at $1.43 per share, down from $2.20 [11] 2026 Guidance - Alkermes expects total revenues for 2026 to be in the range of $1.73-$1.84 billion, primarily driven by net sales of proprietary products projected at $1.52-$1.60 billion [12] - Specific sales forecasts include Vivitrol at $460-$480 million, Aristada at $365-$385 million, and Lybalvi at $380-$400 million [12] - The company anticipates research and development expenses of $445-$485 million and selling, general, and administrative expenses of $890-$930 million [13] Leadership Changes - Alkermes announced that CEO Richard Pops will retire on July 31, 2026, with Blair Jackson appointed as the new CEO effective August 1, 2026 [14] Recent Developments - The company completed the acquisition of Avadel Pharmaceuticals, adding the FDA-approved product Lumryz to its portfolio, which is indicated for narcolepsy [15][16] - Alkermes plans to initiate Phase III studies for alixorexton, a novel treatment for narcolepsy, in Q1 2026 [17]

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products, which generated approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with EBITDA of $285.6 million and adjusted EBITDA of $394 million [11] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, ARISTADA net sales were $370 million, and Lybalvi net sales were $346.7 million for 2025 [9][10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, primarily driven by proprietary products [13] - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with expectations of $350 million to $370 million for 2026 [27][30] Market Data and Key Metrics Changes - The company anticipates manufacturing and royalty revenues in the range of $210 million to $240 million for 2026, reflecting the expiration of certain XEPLION royalties [14] - The estimated market for narcolepsy includes about 200,000 patients in the US, with approximately 80,000 currently being treated [63] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic step to enter the commercial sleep medicine market and enhance the company's product portfolio [6][12] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy [7][31] - The focus remains on operational discipline, efficient capital allocation, and investing in long-term growth opportunities [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, despite anticipated GAAP net losses due to accounting related to the Avadel acquisition [17] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile [20][21] Other Important Information - The transition of CEO from Richard Pops to Blair Jackson is planned for summer 2026, with Pops continuing as chairman [38] - The company is focused on integrating the Avadel team and leveraging their expertise in sleep medicine [29] Q&A Session Summary Question: Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that split dosing is designed to maximize efficacy while minimizing side effects [42][43] Question: Potential synergies across sales forces - The integration of the Avadel commercial team is expected to enhance the company's presence in sleep medicine, with no immediate overlap with the psychiatry sales force [45][46] Question: Evidence needed for payer reimbursement for both drugs - Management believes that both orexin agonists and oxybates will serve different patient needs, and data will be generated to support reimbursement for both [48][49] Question: Internal bar for ESS in LUMRYZ phase 3 - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [54][58] Question: Current understanding of NT1 vs NT2 and IH dynamics - The company acknowledges a significant unmet need in the IH market and plans to wait for phase 2 data before initiating phase 3 discussions with the FDA [60][63] Question: Plans to study LUMRYZ with oxybate - Management sees potential benefits for patients using both treatments and plans to build evidence for reimbursement purposes [67][69] Question: Field force strategy for LUMRYZ - The current sales force is deemed right-sized to target the oxybate-eligible patient segment, with ongoing monitoring of market dynamics [72][74] Question: SG&A spend beyond 2026 - Management indicated that one-time transaction costs will not carry over, and future spending will be controlled with potential synergies from the Avadel acquisition [76][78]

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% in proprietary product sales, amounting to approximately $1.2 billion in net sales [7][8] - The company recorded GAAP net income of $241.7 million, EBITDA of $285.6 million, and adjusted EBITDA of $394 million for the year [10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary product net sales projected between $1.52 billion and $1.6 billion [12] Business Line Data and Key Metrics Changes - VIVITROL net sales for 2025 were $467.9 million, reflecting a 2% growth year-over-year, with expectations for 2026 net sales in the range of $460 million to $480 million [22][23] - ARISTADA net sales were $370 million in 2025, showing a 7% growth year-over-year, with projected 2026 net sales between $365 million and $385 million [24][25] - Bupropion net sales grew 24% year-over-year to $346.7 million in 2025, with expectations for 2026 net sales in the range of $380 million to $400 million [26] Market Data and Key Metrics Changes - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with a significant opportunity to expand the patient base as there are an estimated 50,000 oxybate-eligible patients with narcolepsy [27][29] - The company expects LUMRYZ total revenue for 2026 to be in the range of $350 million to $370 million, with an additional $315 million to $335 million expected for the remainder of the year following the acquisition of Avadel [29] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing Alkermes' entry into the commercial sleep medicine market and providing a platform for the potential launch of alixorexton [4][11] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy, and develop ALKS 7290 and ALKS 4510 for ADHD and fatigue associated with neurodegenerative disorders [5][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing operational discipline and efficient capital allocation [20][21] - The management team highlighted the importance of the upcoming Phase 3 trials for alixorexton and the integration of Avadel's commercial capabilities as key drivers for future success [30][37] Other Important Information - The company ended 2025 with $1.3 billion in cash and total investments, positioning it well for future growth and debt management following the acquisition [11] - Management announced a leadership transition, with Blair Jackson set to take over as CEO, indicating a commitment to continue the company's growth trajectory [37] Q&A Session Summary Question: Regarding the Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that the split dosing is designed to maximize efficacy while minimizing side effects [41][42] Question: Potential synergies between sales forces post-Avaldel acquisition - Management expressed excitement about the integration of the Avadel team and noted that while there is currently little overlap, future synergies are anticipated as the company prepares to launch alixorexton [44][45] Question: Evidence needed for payers to reimburse both oxybates and orexin agonists - Management explained that both treatments may be necessary for certain patients, and they plan to generate data to support the use of both medications [47][48] Question: Internal benchmarks for ESS in the LUMRYZ Phase 3 trial - Management stated that they expect the data from the upcoming study to mirror previous successful profiles and emphasized the importance of secondary endpoints [52][56] Question: Development plans for Valiloxybate - Management indicated that they are moving forward aggressively with Valiloxybate and will assess the need for additional studies based on early data [84][85]

Leadership Transition - Richard Pops, a long-serving CEO of Alkermes, will step down at the end of July, with Chief Operating Officer Blair Jackson succeeding him on July 31 [1][2] - Pops will remain as the board chair and will advise the executive team during the transition [2] Company History and Challenges - Alkermes was founded in 1991 and initially focused on drug delivery, particularly in overcoming the blood-brain barrier [3] - The company faced significant challenges, including the rejection of a depression drug by the FDA in 2019, which led to a stock crash and restructuring [4] - A cancer immunotherapy project was spun out into Mural Oncology, which ultimately failed in clinical testing and accepted a liquidation deal last year [4] Recent Performance and Focus - Alkermes has experienced a steady increase in stock value this decade, with a three-year streak of positive earnings starting in 2023 [5] - The company is focusing more on mental health and sleep medicines, including the schizophrenia treatment Lybalvi and a new class of "orexin" drugs seen as potential blockbusters [5][6] Leadership Recognition - Pops is recognized as a prominent figure in the biotech industry, having served on various boards and being one of the highest-paid CEOs in biopharma [7] - The board expressed gratitude for Pops' leadership and confidence in the organization's future growth under Jackson's leadership [8]

Alkermes Conference Call Summary Company Overview - **Company**: Alkermes - **Industry**: Biotechnology, specifically in neuroscience and sleep medicine - **Key Products**: ALKS 2680 (orexin compound), Vivitrol, Lybalvi, Aristada, Lumryz Core Points and Arguments Financial Performance - In 2025, Alkermes' commercial business generated over **$1.4 billion** in total revenues, demonstrating strong cash flow and profitability [3] - The planned acquisition of Avidel and its product Lumryz is expected to enhance revenue growth and diversify the commercial portfolio [26] Product Development - **ALKS 2680** is entering phase three trials for narcolepsy, following a successful phase two program [3][9] - The drug has been granted **FDA Breakthrough Therapy designation** for narcolepsy type 1 (NT1) [4][30] - The market opportunity for ALKS 2680 in narcolepsy and idiopathic hypersomnia (IH) is projected to exceed **$10 billion annually** [6][8] Market Dynamics - There are approximately **200,000** people in the U.S. with narcolepsy, with only about half diagnosed [6] - Currently, **80,000** patients are receiving treatment for narcolepsy, but **80%** report residual symptoms [7] - The branded pharmaceutical market for narcolepsy treatments, particularly oxybates, is limited, with only **16,000 to 18,000** patients using them annually [8] Clinical Trials and Efficacy - The Vibrance studies demonstrated statistically significant improvements in sleep latency and excessive daytime sleepiness for ALKS 2680 [11] - Approximately **95%** of patients in the studies opted to continue into the safety extension phase, indicating high patient satisfaction [12] - The ongoing phase two study for IH is expected to complete in Q4 2026, with plans to initiate the phase three program shortly after the end-of-phase two meeting with the FDA [15][17] Future Growth and Pipeline - Alkermes plans to develop additional compounds, including **ALK-7290** for ADHD and **ALK-4510** for fatigue associated with neurodegenerative diseases [20][23] - The company aims to leverage its experience in drug development to establish a strong presence in the ADHD market, which includes approximately **15.5 million** adults and **6.5 million** children diagnosed with the condition [22] Competitive Positioning - ALKS 2680 is positioned to compete effectively against Takeda's product due to its broader therapeutic index and multiple dosing options [43][44] - The company emphasizes the importance of rigorous clinical data to create barriers for future competitors [46][47] Additional Important Insights - The acquisition of Avidel is expected to close soon, enhancing Alkermes' entry into the sleep medicine market [10][27] - The company has a strong financial foundation, with over **$1.3 billion** in net sales from its existing products [27] - Alkermes is focused on addressing unmet patient needs in narcolepsy and other sleep disorders, emphasizing the importance of patient-reported outcomes in clinical trials [50][51] This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic direction, product pipeline, and market opportunities.

Core Insights - Alkermes plc is a biopharmaceutical company focusing on neuroscience and oncology, making significant advancements in the sleep medicine market through its acquisition of Avadel and positive results from the Vibrance-2 study [1][5] - The company is experiencing growth, with Lybalvi sales increasing by 32%, contributing to enhanced profitability through favorable gross-to-net dynamics [2][5] - Alkermes' stock is currently priced at $29.60, reflecting a 0.82% increase, with a market capitalization of approximately $4.89 billion and a trading volume of 2,263,843 shares [3][5] Financial and Market Performance - Craig C. Hopkinson, Executive VP of Research and Development, sold 5,000 shares at $30 each, retaining 61,740 shares, indicating confidence in the company's growth trajectory [2][5] - The stock has fluctuated between $29.06 and $30.08 during the trading day, with a yearly high of $36.45 and a low of $25.17, showcasing volatility in the market [3] Clinical Developments - The success of Alixorexton in Phase 2 trials for narcolepsy and idiopathic hypersomnia, along with its clean safety profile, reduces risks in Alkermes' clinical pipeline, positioning the company favorably in the biopharmaceutical landscape [4]

Core Viewpoint - Alkermes reported strong Q3 earnings and raised its 2025 revenue guidance, despite a recent decline in share price and downward estimate revisions from analysts [2][11][13]. Financial Performance - Alkermes reported earnings from continuing operations of 49 cents per share for Q3 2025, exceeding the Zacks Consensus Estimate of 42 cents and up from 56 cents per share in the same quarter last year [2]. - Total revenues for Q3 reached $394.2 million, a 4% increase year-over-year, significantly surpassing the Zacks Consensus Estimate of $355.7 million [3]. - Sales from proprietary products grew 16% year-over-year to $317.4 million, driven by strong demand for Vivitrol, Aristada, and Lybalvi, exceeding management's expectations of $280-$300 million [5]. Product Sales Breakdown - Vivitrol sales increased 7% year-over-year to $121.1 million, beating the Zacks Consensus Estimate of $112.1 million [6]. - Aristada sales rose 16% year-over-year to $98.1 million, surpassing the Zacks Consensus Estimate of $87 million [7]. - Lybalvi generated sales of $98.2 million, up 32% year-over-year, exceeding the Zacks Consensus Estimate of $87.1 million [8]. Revenue Sources - Alkermes' revenue includes net sales from proprietary products and manufacturing/royalty revenues from partnered products [4]. - Manufacturing and royalty revenues decreased approximately 27% year-over-year to $76.8 million, with specific contributions from Biogen's Vumerity and other products [9]. Expense Overview - Research and development expenses totaled $81.7 million, a 36% increase year-over-year, primarily due to ongoing studies on alixorexton [9]. - Selling, general, and administrative expenses reached $171.8 million, up 14% year-over-year, attributed to the expansion of the psychiatry field organization and increased promotional activities for Lybalvi [10]. 2025 Guidance - Alkermes raised its 2025 revenue guidance to a range of $1.43-$1.49 billion, up from the previous range of $1.34-$1.43 billion [11]. - Expected net sales for Vivitrol are now $460-$470 million, Aristada $360-$370 million, and Lybalvi $340-$350 million for the full year [12]. Market Position and Outlook - Despite a recent downward trend in estimates, Alkermes holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [15]. - The company has a subpar Growth Score of D but a better Momentum Score of C, with an aggregate VGM Score of B, indicating a favorable position for value investors [14].

Core Insights - Alkermes plc reported earnings from continuing operations of 49 cents per share for Q3 2025, exceeding the Zacks Consensus Estimate of 42 cents and down from 56 cents per share in the same quarter last year [1][8] - Total revenues for the third quarter reached $394.2 million, a 4% increase year-over-year, significantly surpassing the Zacks Consensus Estimate of $355.7 million [1][8] Revenue Breakdown - Alkermes' proprietary products, including Vivitrol, Aristada, and Lybalvi, generated total sales of $317.4 million, reflecting a 16% year-over-year growth, driven by strong demand [3][4] - Vivitrol sales increased by 7% year-over-year to $121.1 million, exceeding the Zacks Consensus Estimate of $112.1 million [5] - Aristada sales rose 16% year-over-year to $98.1 million, surpassing the Zacks Consensus Estimate of $87 million [6] - Lybalvi achieved sales of $98.2 million, a 32% increase year-over-year, also beating the Zacks Consensus Estimate of $87.1 million [7] Financial Guidance - Alkermes raised its 2025 revenue guidance to a range of $1.43 billion to $1.49 billion, up from the previous range of $1.34 billion to $1.43 billion [13] - The company expects Vivitrol net sales to be between $460 million and $470 million, Aristada sales between $360 million and $370 million, and Lybalvi sales between $340 million and $350 million for the full year [14] Strategic Developments - Alkermes announced a definitive agreement to acquire Avadel Pharmaceuticals for up to $20.00 per share, totaling approximately $2.1 billion, expected to close in Q1 2026 [15] - The acquisition will enhance Alkermes' portfolio with Avadel's Lumryz, a product for treating narcolepsy, projected to generate $265 million to $275 million in net revenues in 2025 [16] - The integration of Avadel is anticipated to create cost synergies and improve operational efficiency, aligning with Alkermes' ongoing development of alixorexton for narcolepsy [17]

Financial Data and Key Metrics Changes - For Q3 2025, total revenues reached $394.2 million, with proprietary products generating net sales of $317.4 million, reflecting a 16% year-over-year growth [11][12] - GAAP net income was $82.8 million, with EBITDA of $96.9 million and adjusted EBITDA of $121.5 million for the quarter [13] - The company raised its full-year 2025 guidance to total revenues of $1.43 billion to $1.49 billion, GAAP net income of $230 million to $250 million, and adjusted EBITDA of $365 million to $385 million [14] Business Line Data and Key Metrics Changes - Vivitrol net sales for Q3 were $121.1 million, driven by growth in the alcohol dependence indication market, with full-year expectations now at $460 million to $470 million [18] - Aristada net sales were $98.1 million for Q3, with full-year expectations raised to $360 million to $370 million [19] - Lybalvi net sales grew 32% year-over-year to $98.2 million, with full-year expectations now at $340 million to $350 million [19] Market Data and Key Metrics Changes - The company experienced strong underlying demand across its proprietary products, with gross-to-net favorability primarily related to Medicaid utilization rates [11][12] - The expansion of the psychiatry sales force contributed to increased prescriber breadth and strong new-to-brand prescriptions [18][19] Company Strategy and Development Direction - The proposed acquisition of Avadel Pharmaceuticals is expected to diversify the commercial portfolio and strengthen profitability, particularly in the sleep medicine market [6][8] - The company is advancing its portfolio of orexin-2 receptor agonists, with a focus on Elixerextant for narcolepsy and idiopathic hypersomnia [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum of the business and the strong commercial performance through the first nine months of the year [5][14] - The company is positioned to deliver long-term value for shareholders while advancing innovative medicines [15][25] Other Important Information - The company entered Q3 with $1.14 billion in cash and total investments, planning to use cash and bank debt for the acquisition of Avadel [14] - Management highlighted the importance of maintaining a disciplined contracting strategy consistent with the value of their medicines [21] Q&A Session Summary Question: Can you talk about Lybalvi's performance and gross-to-net expectations? - Management noted strong performance driven by an expanded psychiatry footprint and increased call volume, with gross-to-net lower due to deductible resets and lower copay utilization [28][30] Question: What are the expectations for NT2 Elixerextant data and FDA next steps? - Management expects to request an end-of-phase meeting with the FDA after receiving NT2 data in November, with plans to initiate the phase three program early next year [34][35] Question: Can you confirm details on the top-line release for Vibrance II data? - Management indicated that top-line data will be released soon, with a focus on safety and efficacy across various doses [43][45] Question: How do you view the potential impact of ACA subsidy lapses on commercial business? - Management believes there is a strong political reason to maintain ACA subsidies, particularly for patients with serious mental illness and addiction [86][88]